{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:30:19Z","timestamp":1786591819612,"version":"build-2736575974"},"reference-count":20,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Pulmonary fibrosis (PF) is a severe, progressive disease, which may be caused by exposure to certain medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We queried the U.S. FDA Adverse Event Reporting System (FAERS) from 2000 to 2022, using the search terms \u201cpulmonary fibrosis\u201d and \u201cidiopathic pulmonary fibrosis\u201d and excluded reports with patients under the age of 18\u2009years, and patients with unknown sex or age. Reports were sorted by generic drug names, counted, and plotted over time using a best\u2010fit trendline based on an exponential function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From 2000 to 2022, there were 24\u2009095\u2009935 adverse drug events reported in FAERS, of which 17\u2009520 (0.07%) were reported as PF. After excluding reports containing patients with unknown age (5255, 30%), sex (122, 0.7%), and age below 18\u2009years old (155, 0.9%), our study included 11\u2009988 reports. The mean age of the study sample was 66.5\u2009\u00b1\u200913.1\u2009years, and 6248 patients (52.1%) were male. Plotting the 11\u2009988 reports by year revealed an exponential best fit line (\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.88) with a positive slope over time. The top five drug classes associated with PF were disease modifying antirheumatic drugs (DMARDs, 39.4%), antineoplastic agents (26.4%), cardiovascular agents (12.6%), corticosteroids (4.6%), and immunosuppressive agents (4.0%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A 23\u2010year analysis of the FAERS database revealed exponentially increasing adverse event reports of PF. Significant annual increases in reporting of PF suspected with DMARDs and antineoplastic agents were identified. Our study highlights important trends, which should be used to guide PF research related to drugs of potential importance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pds.5797","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T03:33:36Z","timestamp":1714361616000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Rising cases of drug\u2010induced pulmonary fibrosis: Analysis of the\n                    <scp>Food and Drug Administration Adverse Event Reporting System<\/scp>\n                    (\n                    <scp>FAERS<\/scp>\n                    ) database, 2000\u20132022"],"prefix":"10.1002","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2061-108X","authenticated-orcid":false,"given":"Kenneth L.","family":"McCall","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice Binghamton University School of Pharmacy &amp; Pharmaceutical Sciences  Johnson City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey R.","family":"Hennig","sequence":"additional","affiliation":[{"name":"Specialty Pharmacy Shields Health Solutions  Stoughton Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary T.","family":"Abe","sequence":"additional","affiliation":[{"name":"School of Pharmacy &amp; Pharmaceutical Sciences Binghamton University  Johnson City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle N.","family":"Dattler","sequence":"additional","affiliation":[{"name":"School of Pharmacy &amp; Pharmaceutical Sciences Binghamton University  Johnson City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karyssa L.","family":"Hurd","sequence":"additional","affiliation":[{"name":"School of Pharmacy &amp; Pharmaceutical Sciences Binghamton University  Johnson City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie L.","family":"Portnoy","sequence":"additional","affiliation":[{"name":"School of Pharmacy &amp; Pharmaceutical Sciences Binghamton University  Johnson City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoey J.","family":"Zagoria","sequence":"additional","affiliation":[{"name":"School of Pharmacy &amp; Pharmaceutical Sciences Binghamton University  Johnson City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01052-2"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(14)70101-8"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.08.016"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/arm91010005"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470059210.ch13"},{"key":"e_1_2_11_7_1","unstructured":"Food and Drug Administration.FDA Adverse Event Reporting System (FAERS) public dashboard.https:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ucm070093.htm. Published October 22 2021. Accessed August 7 2023"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874306401206010063"},{"key":"e_1_2_11_9_1","unstructured":"Food and Drug Administration.National Drug Code Directory.https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/national-drug-code-directoryPublished July 22 2022. Accessed August 7 2023"},{"key":"e_1_2_11_10_1","volume-title":"AHFS Clinical Drug Information","author":"AHFS Classification \u2013 Drug Assignments","year":"2021"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8091312"},{"key":"e_1_2_11_12_1","unstructured":"GraphPad Prism version 9.3.0 for Windows GraphPad Software San Diego California USA.www.graphpad.com"},{"key":"e_1_2_11_13_1","unstructured":"Food and Drug Administration.Coronavirus (COVID\u201019) Update: FDA Authorizes Drug for Treatment of COVID\u201019.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/coronavirus\u2010covid\u201019\u2010update\u2010fda\u2010authorizes\u2010drug\u2010treatment\u2010covid\u201019Published June 24 2021. Accessed August 7 2023"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.103590"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-018-0285-2"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.11.002"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00008014"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijri.IJRI_178_19"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001193"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-016-0455-4"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1323"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5797","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.5797","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:10:53Z","timestamp":1786590653000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1002\/pds.5797"],"URL":"https:\/\/doi.org\/10.1002\/pds.5797","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"assertion":[{"value":"2023-10-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e5797"}}